Literature DB >> 20717741

Prospects of a novel vaccination strategy for human gamma-herpesviruses.

Ting-Ting Wu1, Marcia A Blackman, Ren Sun.   

Abstract

Due to the oncogenic potential associated with persistent infection of human gamma-herpesviruses, including Epstein-Barr virus (EBV or HHV-4) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8), vaccine development has focused on subunit vaccines. However, the results using an animal model of mouse infection with a related rodent virus, murine gamma-herpesvirus 68 (MHV-68, γHV-68, or MuHV-4), have shown that the only effective vaccination strategy is based on live attenuated viruses, including viruses engineered to be incapable of establishing persistence. Vaccination with a virus lacking persistence would eliminate many potential complications. Progress in understanding persistent infections of EBV and KSHV raises the possibility of engineering a live attenuated virus without persistence. Therefore, we should keep the option open for developing a live EBV or KSHV vaccine.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20717741      PMCID： PMC3931126          DOI： 10.1007/s12026-010-8172-z

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


  228 in total

1.  Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism.

Authors:  J W Sixbey; Q Y Yao
Journal:  Science       Date:  1992-03-20       Impact factor: 47.728

2.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

3.  Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins.

Authors:  G Aichinger; L Karlsson; M R Jackson; M Vestberg; J H Vaughan; L Teyton; R I Lechler; P A Peterson
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

4.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

6.  Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency.

Authors:  Qingmei Jia; Michael L Freeman; Eric J Yager; Ian McHardy; Leming Tong; DeeAnn Martinez-Guzman; Tammy Rickabaugh; Seungmin Hwang; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  J Virol       Date:  2009-12-16       Impact factor: 5.103

7.  The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation.

Authors:  Qinmiao Sun; Sunny Zachariah; Preet M Chaudhary
Journal:  J Biol Chem       Date:  2003-10-16       Impact factor: 5.157

8.  Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells.

Authors:  Patrícia A Madureira; Paulo Matos; Inês Soeiro; Linda K Dixon; J Pedro Simas; Eric W-F Lam
Journal:  J Biol Chem       Date:  2005-09-02       Impact factor: 5.157

9.  Lung epithelial cells are a major site of murine gammaherpesvirus persistence.

Authors:  J P Stewart; E J Usherwood; A Ross; H Dyson; T Nash
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

10.  The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation.

Authors:  Jianmin Zuo; Andrew Currin; Bryan D Griffin; Claire Shannon-Lowe; Wendy A Thomas; Maaike E Ressing; Emmanuel J H J Wiertz; Martin Rowe
Journal:  PLoS Pathog       Date:  2009-01-02       Impact factor: 6.823
View more
  10 in total

1.  Importance of antibody in virus infection and vaccine-mediated protection by a latency-deficient recombinant murine γ-herpesvirus-68.

Authors:  Michael L Freeman; Claire E Burkum; David L Woodland; Ren Sun; Ting-Ting Wu; Marcia A Blackman
Journal:  J Immunol       Date:  2011-12-23       Impact factor: 5.422

Review 2.  Activation and Evasion of Innate Immunity by Gammaherpesviruses.

Authors:  Philip T Lange; Maria C White; Blossom Damania
Journal:  J Mol Biol       Date:  2021-08-23       Impact factor: 5.469

3.  CD8(+) T cells from mice transnuclear for a TCR that recognizes a single H-2K(b)-restricted MHV68 epitope derived from gB-ORF8 help control infection.

Authors:  Sharvan Sehrawat; Oktay Kirak; Paul-Albert Koenig; Marisa K Isaacson; Sofia Marques; Gunes Bozkurt; J Pedro Simas; Rudolph Jaenisch; Hidde L Ploegh
Journal:  Cell Rep       Date:  2012-04-26       Impact factor: 9.423

4.  The anti-interferon activity of conserved viral dUTPase ORF54 is essential for an effective MHV-68 infection.

Authors:  Ronika Sitapara Leang; Ting-Ting Wu; Seungmin Hwang; Lidia T Liang; Leming Tong; Jennifer T Truong; Ren Sun
Journal:  PLoS Pathog       Date:  2011-10-06       Impact factor: 6.823

5.  Global mRNA degradation during lytic gammaherpesvirus infection contributes to establishment of viral latency.

Authors:  Justin M Richner; Karen Clyde; Andrea C Pezda; Benson Yee Hin Cheng; Tina Wang; G Renuka Kumar; Sergio Covarrubias; Laurent Coscoy; Britt Glaunsinger
Journal:  PLoS Pathog       Date:  2011-07-21       Impact factor: 6.823

Review 6.  KSHV targeted therapy: an update on inhibitors of viral lytic replication.

Authors:  Natacha Coen; Sophie Duraffour; Robert Snoeck; Graciela Andrei
Journal:  Viruses       Date:  2014-11-24       Impact factor: 5.048

7.  Immune Control of γ-Herpesviruses.

Authors:  Philip G Stevenson
Journal:  Viral Immunol       Date:  2019-07-22       Impact factor: 2.257

8.  Deletion of immune evasion genes provides an effective vaccine design for tumor-associated herpesviruses.

Authors:  Gurpreet Brar; Nisar A Farhat; Alisa Sukhina; Alex K Lam; Yong Hoon Kim; Tiffany Hsu; Leming Tong; Wai Wai Lin; Carl F Ware; Marcia A Blackman; Ren Sun; Ting-Ting Wu
Journal:  NPJ Vaccines       Date:  2020-11-05       Impact factor: 7.344

9.  Gammaherpesvirus infection modulates the temporal and spatial expression of SCGB1A1 (CCSP) and BPIFA1 (SPLUNC1) in the respiratory tract.

Authors:  Gail H Leeming; Anja Kipar; David J Hughes; Lynne Bingle; Elaine Bennett; Nathifa A Moyo; Ralph A Tripp; Alison L Bigley; Colin D Bingle; Jeffery T Sample; James P Stewart
Journal:  Lab Invest       Date:  2014-12-22       Impact factor: 5.662

10.  From Superantigens to "Real" Viral Antigens.

Authors:  Marcia A Blackman
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.